Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Gh save search
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -0.75%
H: 4.38%
C: 2.7%
test health cancer study
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
Published: 2024-01-17 (Crawled : 14:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -2.21%
H: 3.0%
C: 2.48%
health asco cancer colon
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Published: 2024-01-08 (Crawled : 09:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 2.99%
H: 1.81%
C: 1.36%
health genomic cancer africa
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
Published: 2023-12-04 (Crawled : 12:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.04%
H: 4.56%
C: 2.24%
health cancer research collaboration
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 1.51%
H: 3.92%
C: -1.29%
disease breast health symposium biomarker cancer therapy
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
Published: 2023-11-13 (Crawled : 00:00) - prnewswire.com
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 2.73%
H: 2.12%
C: 2.07%
test health cancer
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Published: 2023-10-23 (Crawled : 09:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -0.51%
H: 5.33%
C: 1.88%
cancer treatment trial promise colon results show
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Published: 2023-09-05 (Crawled : 18:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.0%
H: 7.57%
C: 0.86%
guardant360 lung japan diagnostic health her2 approval cancer cell treatment companion
Global Colorectal Cancer Screening Market Report 2023: Sector is Expected to Reach $9.73 Billion by 2033 at a CAGR of 15.94%
Published: 2023-06-16 (Crawled : 19:00) - prnewswire.com
DHR | $236.36 -1.27% 0.0% 4.2M
|
Health Technology
| Email alert
Add to watchlist
EXAS | $63.45 0.36% 0.36% 1.6M
|
Health Technology
| Email alert
Add to watchlist
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
| Email alert
Add to watchlist
report expected reach cancer global market
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
Published: 2023-05-31 (Crawled : 14:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -0.03%
H: 2.65%
C: 2.34%
health asco cancer blood meeting
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Published: 2023-04-25 (Crawled : 14:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -0.95%
H: 0.0%
C: -6.13%
institute health cancer treatment research immunotherapy collaboration response biomarkers study
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
Published: 2023-04-21 (Crawled : 13:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.77%
H: 0.24%
C: -1.13%
disease health cancer technology week potential
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
Published: 2023-04-18 (Crawled : 15:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 1.92%
H: 0.0%
C: -3.65%
health guardant360 cancer immunotherapy response
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.63%
H: 3.41%
C: 2.16%
health cancer meeting
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
Published: 2023-03-21 (Crawled : 18:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.35%
H: 3.61%
C: 1.96%
health state cancer study
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Published: 2023-02-15 (Crawled : 16:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.29%
H: 3.64%
C: 3.46%
blood test impact health cancer study
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -0.11%
H: 9.85%
C: 4.35%
guardant360 blood lung test diagnostic breast health cancer
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: 0.52%
H: 3.45%
C: 1.29%
analytics health biomarker cancer
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -1.0%
H: 0.96%
C: -0.93%
guardant360 treatment fda diagnostic breast health approval cancer esr1 mutation orserdu her2- her2 metastatic breast cancer
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -1.0%
H: 0.93%
C: -0.03%
treatment blood test health trial trust cancer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.